Assenagon Asset Management S.A. Trims Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Assenagon Asset Management S.A. lessened its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 94.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,172 shares of the biopharmaceutical company's stock after selling 96,908 shares during the quarter. Assenagon Asset Management S.A.'s holdings in TG Therapeutics were worth $243,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Arizona State Retirement System boosted its position in TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock valued at $1,283,000 after acquiring an additional 364 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 371 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of TG Therapeutics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after purchasing an additional 463 shares during the last quarter. NBC Securities Inc. lifted its holdings in shares of TG Therapeutics by 82,300.0% during the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 823 shares during the last quarter. Finally, New York State Teachers Retirement System lifted its holdings in shares of TG Therapeutics by 1.9% during the 4th quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock valued at $1,317,000 after purchasing an additional 837 shares during the last quarter. Institutional investors own 58.58% of the company's stock.

Analyst Upgrades and Downgrades

TGTX has been the subject of several analyst reports. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $40.80.

Insider Buying and Selling

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the transaction, the director now owns 228,816 shares in the company, valued at approximately $8,452,463.04. This trade represents a 4.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 10.64% of the stock is currently owned by company insiders.

TG Therapeutics Stock Performance

TGTX stock traded up $0.54 during midday trading on Monday, reaching $36.56. The stock had a trading volume of 1,580,158 shares, compared to its average volume of 2,943,454. The stock has a market cap of $5.80 billion, a PE ratio of 152.33 and a beta of 1.94. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.04 and a current ratio of 4.02. The firm has a fifty day simple moving average of $37.15 and a two-hundred day simple moving average of $34.87. TG Therapeutics, Inc. has a 52-week low of $16.65 and a 52-week high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The firm had revenue of $120.86 million during the quarter, compared to analysts' expectations of $117.07 million. TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The business's revenue was up 90.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.07) EPS. As a group, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.